Sharks, and other members in Chondrichthyes, produce, apart from the expected IgM and IgW, a type of ancestral antibody referred to immunoglobulin new antigen receptor (IgNAR). IgNAR antibody is composed of only a homodimeric heavy chain which contains one variable and five constant domains for each chain. The distinct structure of IgNAR domains leads to […]
| Inventor | Institute |
|---|---|
| Ayham Alnabulsi | Vertebrate Antibodies Limited |
| Cat. #: | 153311 |
|---|---|
| Unit size: | 100 ug |
| Application: | ELISA ; WB |
| Target: | IgNAR immunoglobulin heavy chain membrane and secretory forms |
| Reactivity: | Small-spotted catshark |
| Clone: | V39 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Small-spotted catshark IgNAR, IgNAR antibody, Nanobody, Single domain antibody |
|---|---|
| Product description: | Sharks, and other members in Chondrichthyes, produce, apart from the expected IgM and IgW, a type of ancestral antibody referred to immunoglobulin new antigen receptor (IgNAR). IgNAR antibody is composed of only a homodimeric heavy chain which contains one variable and five constant domains for each chain. The distinct structure of IgNAR domains leads to extremely high stability. In addition, VNAR is around 10 times smaller than standard antibodies and able to continue to function and exist within very extreme conditions. These properties allow IgNAR to penetrate tissues easier in vivo to improve bioavailability for pharmaceutical applications. Anti-IgNAR antibody (V39) can be used to monitor IgNAR levels in shark following immunization |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | Ovalbumin-conjugated short synthetic peptide |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | Sharks, and other members in Chondrichthyes, produce, apart from the expected IgM and IgW, a type of ancestral antibody referred to immunoglobulin new antigen receptor (IgNAR). IgNAR antibody is composed of only a homodimeric heavy chain which contains one variable and five constant domains for each chain. The distinct structure of IgNAR domains leads to extremely high stability. In addition, VNAR is around 10 times smaller than standard antibodies and able to continue to function and exist within very extreme conditions. These properties allow IgNAR to penetrate tissues easier in vivo to improve bioavailability for pharmaceutical applications. Anti-IgNAR antibody (V39) can be used to monitor IgNAR levels in shark following immunization |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.